qfx

Both of these funds, you understand, are constructed to mimic the price of gold bullion itself. For the investor who wishes to dabble in precious metals without the bother of a safe deposit box and a burly guard, they offer a remarkably straightforward solution. However, a closer inspection reveals a few subtle differences, rather like discerning the cut of a diamond – only a keen eye will truly appreciate the nuance.

Until recently, one had to suffer the indignity of an injection to partake of these weight-loss wonders. Novo Nordisk, bless their innovative spirit, led the charge with Wegovy. But Lilly’s Mounjaro and Zepbound, dashingly clever concoctions, quickly gained ground. However, the game, as they say, is afoot once more. Novo Nordisk, exhibiting a commendable sense of timing, has introduced a pill version of Wegovy. A pill, you understand, is infinitely more agreeable than a needle. Lilly is, naturally, working on its own offering, but Novo Nordisk has a distinct head start – a chance to regain some lost ground while the field remains, shall we say, somewhat sparsely populated by pill-based solutions.

By the market’s close, the company’s stock had shed more than a quarter of its value. A rather dramatic depreciation, even for an era accustomed to fleeting fortunes. It seems the public’s appetite for indoor exertion has, shall we say, cooled.